Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
Following the CHMPs positive opinion, theEuropean Commissionwill render an official decision as to the authorization of the use of TAVNEOS in the European Union in January 2022.
- Following the CHMPs positive opinion, theEuropean Commissionwill render an official decision as to the authorization of the use of TAVNEOS in the European Union in January 2022.
- ViforPharmahas granted Kissei Pharmaceutical Co., Ltd. an exclusive license to commercialize TAVNEOS (avacopan), in Japan, where TAVNEOS was approved for use in ANCA vasculitis patients in September.
- Vifor Pharma will pay ChemoCentryx royalties in the teens to the mid-twenties percent on potential ex-US net sales off one aggregate net sales line.
- Please click here for Patient Information for TAVNEOS in the United States, including Important Safety Information and Full Prescribing Information.